Astaxanthin, a marine-derived xanthophyll carotenoid largely distributed in shrimp waste, has attracted considerable interest for its potent anti-inflammatory properties and unique molecular structure. In this study, an eco-friendly extraction method was developed for the extraction on astaxanthin from processing waste of red blue shrimp Aristeus antennatus (Risso, 1816) collected in Mostaganem, Algeria. The anti-inflammatory effect of astaxanthin extract was investigated in vitro and in silico two key inflammatory mediators, NF-κB and COX-2. A maximum yield of 264.96 μg/g of shrimp waste using sunflower oil at solid-to-liquid ratio of 1:10 at 60 °C for 60 min. The anti-inflammatory activity of the extracted astaxanthin was evaluated in vitro using a bovine serum albumin denaturation assay, where astaxanthin demonstrated a clear, dose-dependent inhibition, achieving 64% inhibition at 250 µg/mL compared to 80% for the reference drug diclofenac. In silico molecular docking revealed strong binding affinities of astaxanthin to both the p50/p65 subunit of NF-κB (–7.9 kcal/mol) and the COX-2 enzyme (–10.4 kcal/mol), with detailed interaction analyses highlighting key hydrophobic, hydrogen bonding, and π-σ orbital contacts that underpin its dual-target specificity. ADMET predictions indicated limited oral bioavailability due to high lipophilicity, but a favorable safety profile and low risk of cytochrome P450-mediated interactions.

This study proposes an innovative method for automated health status method shows significant potential for telemonitoring classification based on the analysis of two critical physiological parameters: Oxygen Saturation (SpO₂) and Heart Rate (HR). Using an optimized decision tree algorithm, we developed a model capable of discriminating between four clinical conditions with an overall accuracy of 96.2%. The results demonstrate the effectiveness of this approach for preliminary diagnosis while providing clear interpretation of decision rules, which is essential for medical applications. This and early warning systems.

Background and aim of the study: Comparison of post-operative analgesic efficacy of morphine and dexmedetomidine as an adjuvant to bupivacaine in erector spinae plane block (ESP) in patients undergoing lumbar spine surgery was done in this study. Material and Methods: This was a randomized, double-blinded comparative study conducted in a tertiary care center. Ninety patients of age 16-60 years, with American Society of Anesthesiologists (ASA) status I or II, undergoing elective lumbar spine surgery were included in the study. patients were randomized into two groups: group M (n=45) and group D (n=45). Erector spinae plane block was performed under ultrasound guidance using 0.5 ml/kg of 0.25% of bupivacaine with morphine 50 mcg/kg (group M) and dexmedetomidine 1mcg/kg (group D). Numeric rating scale for post-operative pain assessment, perioperative hemodynamic parameters, perioperative time for first rescue analgesia and incidence of complications were recorded. Statistical tests were applied as follows: qualitative variables were correlated using the Chi-square test or Fisher’s exact test and quantitative variables were compared using independent t-test or Mann-Whitney test between the two groups. Results: Pain was assessed using Numeric rating scale in the postoperative period at 1, 2, 4, 6, 8, 12, 18, 24 h. Mean NRS pain score was found to be lower in group M than group D at all time intervals in the post-operative period which was statistically significant with p value (<0.05). mean ± standard deviation (SD) for first rescue analgesia time was 13.76 ± 2.57 hours in group M and 7.20 ± 1.68 hours in group D which was found to be statistically significant with p value (<0.001). Post-operative nausea (66% vs 13%) and vomiting (22% vs 6%) was significantly higher in group M as compared to group D which was significant with p value (<0.001). Conclusion: Ultrasound guided erector spinae plane block using 0.25% bupivacaine with morphine and dexmedetomidine provided adequate analgesia during post-surgery in patients undergoing lumbar spine surgery. The risqué analgesic requirement during the first 24 hours was also decreased.